In order to develop more selective methods for labeling brain dopamine receptors, this study describes in detail the properties of 2-amino-6,7-["H]dihydroxy-1,2,3,4-tetrahydronaphthalene (["HI ADTN) binding to dopaminergic sites in rat, calf, and human brain.
not stimulate adenylate cyclase (Kebabian and Calne, 1979) but which now appear to be linked to the inhibition of adenylate cyclase (Munemura et al., 1980; Cote et al., 1981; Meunier and Labrie, 1981) . DP receptors have been labeled by 3H-neuroleptics (of the butyrophenone class) and 3H-ergots (Burt et al., 1976; Seeman et al., 1976b; Leysen et al., 1978; Caron et al., 1978; Baudry et al., 1979) . Dz receptor sites generally exhibited nanomolar (i.e., high affinity) dissociation constants for these 3H-ligands but were occupied only by micromolar (i.e., low affinity) concentrations of the agonists dopamine, apomorphine, and ADTN ((+)-6,7-dihydroxy-2-aminoTetralin). Studies have indicated, however, that 3H-butyrophenone neuroleptics also label sites with high affinity for both neuroleptics and dopamine agonists. The two sites have been called Dz and Dd (List and Seeman, 1981) , respectively (or D-4 and D-2 (Sokoloff et al., 1980b) or Dz low and Dz high (Sibley et al., 1981) ). It has been suggested that these two apparent binding sites (labeled by 3H-butyrophenones) actually may be different states of the same Dz receptor (Sibley et al., 1981) .
A third distinct dopaminergic binding site, which we now call D.7 (Titeler et al., 1979; , has been detected in the calf caudate using [3H]dopamine, ["Hlapomorphine (Seeman et al., 1975 (Seeman et al., ,1976b Burt et al., 1975 Burt et al., , 1976 , and r3H]ADTN Cross et al., 1979) . This site is characterized by its high affinity (with KU values of 1 to 10 nM) for dopamine, as well as other dopaminergic catecholamines, such as apomorphine and ADTN, and its low affinity for potent neuroleptics (with KU values of 100 nM and greater). We have reported recently that a binding site with D3 properties can be detected in dopaminergic areas of the rat and human brain, as well as the calf brain, using ["Hldopamine .
[3H]Apomorphine and ["HIADTN, however, often have appeared to label sites in the rat brain different from those detected in the calf . One of the problems with r3H] apomorphine and [3H]ADTN is that these ligands appear to label multiple sets of binding sites in rat brain. Using ["HIADTN and [3H] apomorphine, , for example, have demonstrated biphasic drug competition curves against these ligands. In these studies, however, no attempt was made to label selectively and characterize the binding of these ligands to separate populations of sites. Drug I&O values reported by these workers thus represent a combination of the IC& values of different populations of ["Hlapomorphine or [3H] ADTN binding sites. Recently, Sokoloff et al. (1980a, b) have demonstrated that [3H]apomorphine in rat striatum can bind to the D.1 site as well as to another distinctly different site characterized by a high affinity for both dopamine and dopaminergic catecholamines and neuroleptics.
We have now re-examined ["HIADTN binding in order to label selectively and characterize the various dopaminergic binding sites labeled by this ligand in rat, calf, and human brain.
Materials and Methods Tissue preparation.
Brains from calves (Hunnisett plant, Canada Packers Co.) or from rats (male Wistar, 200 to 250 gm, sacrificed by cervical dislocation) were removed immediately after death, stored in ice (calf) or in ice cold saline (rat), and dissected within 1 to 2 hr after death. Neurologically normal human brains were obtained from individuals (22 to 91 years of age) who had died from pneumonia or myocardial infarction or in car accidents. After removal from the cranium (3 to 25 hr postmortem), human brains were stored frozen. For dissection, human brains were removed from storage and allowed to reach approximately 0°C to allow the cutting of coronal sections. The sections then were dissected on glass plates over dry ice.
Dissected regions from brains of calf, rat, and human were placed in 15 vol of cold TEAN buffer (15 mM TrisHCl, pH 7.4, 5 mu NazEDTA, 0.02% (1.1 ITIM) ascorbate, and 12.5 PM nialamide), briefly Teflon glass homogenized, centrifuged (44,000 x g), resuspended (15 vol) four times (in order to remove endogenous dopamine), and finally stored frozen (-2O"C, 3-to 5-ml aliquots of 180 to 300 (calf), 35 (rat), or 40 mg (human), original wet weight/ ml). Before final use, the suspension was diluted (calf only) and Polytron homogenized (Brinkmann PT-10, setting of 7, 10 set).
Binding studies. Assays were carried out using quadruplicate glass test tubes (12 x 75 mm) which received in order: 200 ~1 of buffer (with or without competing nonradioactive drug), 200 ~1 either of [3H]ADTN (25 to 35 Ci/mmol, New England Nuclear, Boston) or [3H]apomorphine (39 Ci/mmol, New England Nuclear, Boston), and 200 d of tissue (0.3 to 0.4 mg of protein for calf; 0.4 to 0.5 mg of protein for rat, or 0.5 mg of protein for human). After incubation at 20 to 22'C for 30 min, 0.5-ml aliquots were vacuum-filtered through Whatman GF/ B filters, followed by a 10-n-J wash with buffer. Filters were inserted into liquid scintillation vials along with either 8 ml of Aquasol (New England Nuclear, Boston) or ACS (Amersham, Arlington Heights, IL) and equilibrated for at least 12 hr before the determination of radioactivity.
Unless specified, all results expressed were averaged for two to five individual experiments. Binding isotherms and Scatchard analyses were done using Fig. 3 under "Results"). Selective binding to the population of sites with high affinity for dopaminergic catecholamines and low affinity for neuroleptics (D3 sites) was defined as that binding occurring in the presence of 30 nru spiperone (to occlude the high affinity sites for neuroleptics) and displaceable by 1 PM apomorphine or dopamine. In drug competition experiments against 3H-ligand binding, drug ICsO values were defined as that concentration of drug required to inhibit 50% of the specific binding. If drugs exhibited two clearly separate high affinity and low affinity phases in their competition for specific 3H-ligand binding, separate ICsO values were determined for each phase of competition. I& values for the first and second phases of competition were defined as those drug concentrations required to inhibit 50% of the high affinity phase binding and 50% of the low affinity phase binding, respectively. Hill coefficients for drug competition curves were determined from the slope (m) of the line: than the other drugs, as usually found in self-competition data (Seeman, 1980) . As shown in Table I , column 2, the dopamine catecholamine agonists (NPA (N-propyl norapomorphine), ADTN, apomorphine, and dopamine) were most potent at inhibiting specific binding of [3H]ADTN (with I& values of 3 to 10 nM), while the dopaminergic ergots (LSD (lysergic acid diethylamide) , DHEC (dihydroergocryptine), and bromocryptine) were somewhat less potent (with IGo values of 13 to 60 nM). Neuroleptic drugs showed a wide range of IGO values; piflutixol had the lowest IC& value (13 no), while drugs such as metoclopramide and domperidone had IGO values of greater than 1000 nM. While norepinephrine was quite potent at inhibiting r3H]ADTN binding, both (Y-and /?-adrenergic antagonists were very weak at inhibiting binding.
Competition curves against [3H]ADTN, particularly those of neuroleptics, had Hill coefficients significantly less than unity (Table I) . Such Hill coefficients can indicate the presence of either negative cooperativity or multiple sites for ligand binding. However, it is strongly suggested from the biphasic competition curves of domperidone, spiperone, sulpiride, and metoclopramide (Figs. 1 and 3), which showed a clear separation between the high affinity and low affinity phases of competition, that [3H]ADTN was labeling more than one binding site. These neuroleptics and others (not shown) demonstrated high affinity competition leveling at 72 to 78% of the total binding, followed by a lower affinity competition phase leveling at 45 to 50% of the total binding. Thus, 0.9 nM [3H]ADTN appeared to label at least two sites; almost half of the specific binding was associated with a high affinity site for neuroleptics, while the remaining specific binding was associated with a low affmity site for neuroleptics. Table II lists I& values at the two sites for neuroleptics having clearly separate high affinity and low affinity phases of competition.
As shown in Figures 1, 2 (top), and 3 (top), the catecholamines, ergot dopamine agonists, and some neuro- dopamine. The points are averages (+-SEM) for three to five experiments. Vol. 2, No. 7, July 1982 15% of the total binding, indicating that about 17% of all specific binding was to the high affinity site for neuroleptics, while the remainder of the binding was to sites with low affinity for neuroleptics. As shown in Figure 5 (bottom) and in Table IV , the addition of 30 no spiperone to the assay system resulted in the elimination of the high affinity phase of neuroleptic competition and in an increase of the I& value and Hill coefficient for the neuroleptic, piflutixol. In contrast, the I(&, values and Hill coeffkients for the catecholamine agonists were little affected.
[3H]ADTN competition curves in human caudate. Dopaminergic catecholamines were very potent in competing (with somewhat shallow curves) for approximately 55% of the total [3H]ADTN binding (Fig. 6) lo-'0 lo-'0 10-g 10-g 10-e 10-e 10-7 10-7 1 O-6 1 O-6 10-5 10-5 Figure  5 . , to describe those sites with high affinity for dopamine and low affinity for neuroleptics. Representative Scatchard analyses in rat, calf, and human for [3H] ADTN binding to all specific sites, the D3 sites, and the high affinity sites for neuroleptics are shown in Figure 7 . In the calf, the densities of the DB sites and the high affinity neuroleptic sites were approximately 160 to 170 fmol/mg of protein and 39 to 55 fmol/mg of protein, respectively (as measured by [3H]ADTN or [3H]apomorphine). Compared to the rat, the calf had about 150% more Ds sites and 34% fewer high affinity neuroleptic sites.
No sites with high affinity for neuroleptics were detected in the calf or rat using [3H]dopamine. As shown in Table VI 
Discussion
The present study demonstrates that [3H]ADTN binds to two distinct dopaminergic sites and provides an approach for the selective labeling of these sites individually. One site labeled by [3H]ADTN appears to be the D3 site, characterized by its high affinity for dopaminergic catecholamines and its low affinity for neuroleptics (previously identified using [3H]dopamine (Sokoloff et al., 1980a, b) . Our present work indicates that, under our assay conditions, ["HIADTN and [3H] apomorphine label both of the above described sites, while at low (nanomolar) concentrations, [3H]dopamine labels only D3 sites.
Catecholamine dopamine agonists (including dopamine, apomorphine, and NPA) in rat striatum and calf and human caudate competed for the same amount of total r3H]ADTN binding. In the rat and human brain, ADTN itself competed for somewhat more ["HIADTN binding (5 to 10% more) than other drugs. As these sites had no affinity for any of the dopamine-related drugs tested, it appears that [3H]ADTN may label some nondopaminergic radioligand-specific sites (a phenomenon previously observed using [3H]apomorphine (Leysen and Gommeren, 1981) and [3H]spiperone (Howlett et al., 1979) ). Neuroleptics competed for the same amount of [3H]ADTN binding as the dopaminergic catecholamine agonists. Many neuroleptics, however, (e.g., chlorpromazine, haloperiodol, spiperone, metoclopramide, sulpiride, and domperidone) showed two distinctly separate phases to their competition. I&o values of the low affinity neuroleptic competition were similar to neuroleptic I&O values for the D3 site . In order to determine whether [3H]ADTN could label these same Vol. 2, No. 7, July 1982 Rat Striatum binding to the sites with high affinity for binding in rat striatum produced distinctly separate high neuroleptics but not the sites with low affinity for neu-affinity and low affinity phases, similar to those observed roleptics.) As shown in Figure 8 , in the presence of 30 nM using [3H]ADTN (Fig. 4) . In contrast, [3H]dopamine at low concentrations (i.e., less than 1 nM) appeared to label only Da sites as indicated by the absence of a high affinity phase for neuroleptic competition (Fig. 4) .
In order to measure the number of D3 sites and high affinity neuroleptic sites labeled by ["HIADTN,
[3H]apomorphine, and ["Hldopamine, Scatchard analyses were done under conditions which allowed selective labeling of these two types of sites in the calf and rat brain ( Fig.  7 ; Table VI) . ["HIADTN and [3H] apomorphine detected both the Ds sites and the sites with high affinity for neuroleptics. The B,,, values of each site were similar regardless of which ligand was used, further supporting the suggestion that both ligands were labeling the same two sites. The B ,,,aX value obtained for all specific displaceable binding was equal to the sum of the densities for the D3 and the high affinity neuroleptic sites, indicating that no other sites were being labeled significantly. We have demonstrated previously ) that the D1( site labeled by [3H]dopamine was distributed only in dopaminergic areas of the brain and was heat labile. These observations supported the dopaminergic nature of this binding site. Similarly, the dopaminergic nature of the second site, labeled by ["HIADTN and ["HI apomorphine, with high affinity for neuroleptics, was supported by the failure of the present study to detect this site in preparations of boiled rat striatum and in the non-dopaminergic brain area, cerebellum.
The number of D3 sites compared to the number of high affinity neuroleptic sites (labeled by ["HIADTN or [3H] apomorphine) varied considerably between species. In terms of actual densities, the rat striatum contained almost equal amounts of both sites, while in the calf, D3 sites were 3-fold higher in density than the high affinity neuroleptic site. In neuroleptic competition experiments against 0.8 to 0.9 nM [3H]ADTN, the high affinity phase comprised approximately 50% of the specific binding in the rat, 25% of the specific binding in the human, and only about 17% of the specific binding in the calf. Several studies have found considerable differences in the ["HI ADTN and ["Hlapomorphine IGO values between the calf and the rat Davis et al., 1980) . The present results suggest that this difference may be due in part to the greater contribution of the high affinity neuroleptic site to ["HI apomorphine and ["HIADTN binding in the rat compared to the calf. The low proportion of these high affinity neuroleptic sites in the calf caudate is consistent with previous work from a number of laboratories which failed to note the presence of these sites and which reported drug ICsO values against the binding of ["HI apomorphine and [3H]ADTN in the calf under nonselective conditions, which agree well with IGo values obtained at the D3 site (Burt et al., , 1976 Seeman et al., 1976b Thal et al., 1978; Cross et al., 1979; Titeler et al., 1979) . If the D3 site is labeled selectively by ["HI dopamine or by ["HIADTN (in the presence of 30 nM spiperone; this study), the binding characteristics of these ligands correlate well between species.
Differences in the assay conditions also may play a role in directing ["HIADTN or ["Hlapomorphine primarily to the D3 site or the high affinity neuroleptic site. While [3H]ADTN under our assay conditions had an equal affinity for both sites in the rat, [3H]apomorphine had a 2-fold higher affinity for D3. Consistent with these results, we have found previously that, using low concentrations (0.5 n&i) of [3H]apomorphine, binding was predominantly to D3 sites (Titeler et al., 1979) . Leysen (1979) ) using higher concentrations of [3H]apomorphine and a slightly different buffer, appeared to label predominantly the sites with high affinity for neuroleptics.
Large differences in the effects of brain lesions on the binding of "H-catecholamine agonists have been observed between laboratories Nagy et al., 1978; Leysen, 1979; Weinreich and Seeman, 1980) . These differences, however, may be due to the fact that these ligands can label multiple sites. Under conditions where the D3 site was primarily labeled, kainic acid lesions of the striatum had no effect, while 6-OH-dopamine lesions of nigrostriatal dopamine neurons reduced binding, indicating that at least some of the D3 sites are presynaptic (Nagy et al., 1978; Weinreich and Seeman, 1980; Sokoloff et al., 1980b) . In contrast, Leysen (1979) found that ["Hlapomorphine binding was unchanged after 6-OH-dopamine lesions and was reduced by kainic acid. In the study by Leysen (1979) , however, as previously discussed, [3H]apomorphine appeared to label a considerable number of the high affinity sites for neuroleptics. Consistent with these findings, using procedures which selectively label the high affinity neuroleptic sites with ["Hlapomorphine, Sokoloff et al. (1980b) Vol. 2, No. 7, July 1982 have shown that these sites were increased or unaffected by 6-OH-dopamine lesions and were reduced significantly by kainic acid. These results suggest that some of the high affinity sites for neuroleptics are postsynaptic.
The biological relevance of a number of the now described dopaminergic sites and their relationship to dopaminergic pharmacology is still unclear. Dopamine receptor terminology often classifies receptors into two types. D1 dopamine receptors have been defined by their ability to stimulate adenylate cyclase activity while Dz dopamine receptors have been defined as those which do not stimulate cyclase activity (Kebabian and Calne, 1979) . D1 at present fulfills some, but not all, of the criteria for a bona fide dopamine receptor. The dopamine-stimulated cyclase has a pharmacology which is dopaminergic in nature, it is distributed in dopaminergic regions of the brain, and it can be specifically and saturably labeled using cis-[3H]flupenthixol or [3H]piflutixol (Clement-Cormier and Robison, 1977; Hyttel, 1978 Hyttel, , 1981 . The affinities or potencies of drugs at the dopamine-stimulated cyclase, however, do not correlate with the pharmacology of any yet known dopamine-mediated behavior or biological effect.
DS show a dopaminergic pharmacology quite distinct from that of D1. In contrast to D1, the affinities of neuroleptics for Dz correspond well to their potencies as antagonists for various dopamine-mediated events, such as apomorphine-induced stereotypy, turning, and emesis as well as dopamine inhibition of prolactin secretion in the pituitary Leysen et al., 1977; Caron et al., 1978; Seeman, 1980) . The affinity of neuroleptics for the DZ receptor (labeled by ["Hlhaloperidol and ["Hlspiperone) also has been shown to correlate well with the potencies of these drugs in treating schizophrenia (Seeman et al., 1976a) . There is evidence now indicating that (in the pituitary at least) there are DP dopamine receptors with nanomolar affinity for dopamine and neuroleptics which produce their biological responses via a dopamine-inhibited cyclase (Munemura et al., 1980; Cote et al., 1981; Meunier and Labrie, 1981) .
The D:! receptor sites, labeled by "H-butyrophenones and "H-ergots, usually have been typified by a high affinity for potent neuroleptics (with I& values of 1 to 30 nM) and a low affinity for dopaminergic catecholamines, such as dopamine, apomorphine, and ADTN (with I&o values of 100 to 10,000 nM) (Seeman et al., 1975 (Seeman et al., , 1976a Burt et al., 1976; Titeler et al., 1977; . As one of the sites labeled by ["HI ADTN in our present study had a high affinity for neuroleptics as well as for dopaminergic catecholamines, one might expect "H-butyrophenones to label this site as well (specifically by low (nanomolar) concentrations of [3H]spiperone, ["Hldomperidone, or [3H] haloperidol, since these neuroleptics had low IC& values (ranging from 0.15 to 3 nM) for this [3H]ADTN binding site in the present study). Present work has indeed suggested, and more recent work has demonstrated, that ["Hlspiperone and ["Hlhaloperidol label not only sites with high affinity for neuroleptics and low affinity for dopaminergic catecholamines but also sites with high affinity for both neuroleptics and dopaminergic catecholamines (Titeler et al., 1978b; Howlett and Nahorski, 1980; Sokoloff et al., 1980b) . These two sites labeled by "H-butyrophenones may be interconvertible through the use of ions and GTP (Sokoloff et al., 1980b; Sibley et al., 1981) . Based on this evidence and extrapolating from the studies of other adenylate cyclase-linked receptors, Sibley et al. (1981) have suggested that the two apparent binding sites labeled by 3H-butyrophenones may represent high affinity and low affinity agonist states of the Da receptor. Drug IC, values for the site with high affinity for neuroleptics, labeled in the present study by ["HI ADTN, are very similar to drug I& values for the site with high affinity for dopaminergic catecholamines and neuroleptics labeled by the "H-butyrophenones. Our present results thus support the suggestion by Sokoloff et al. (1980b) that [3H]apomorphine and ["HIADTN (present study) label a site that also is labeled by the "Hneuroleptics (i.e., a site with high affinity for both dopaminergic catecholamines and neuroleptics).
Thus, the two sites in the brain labeled by [JH] apomorphine and [3H]ADTN appear to be the D:s site and possibly a high affinity state of the Dz receptor.
Some D3 sites, as discussed, appear to have a presynaptic location on dopamine nerve terminals, which makes them a possible candidate for the dopamine autoreceptor (Carlsson, 1977; Titeler et al., 1978a) . While the binding properties of the D3 site are well known (high affinity for dopamine, low affinity for neuroleptics), the pharmacology of the autoreceptor is not very well characterized. If the D3 site is the dopamine autoreceptor, one would expect the autoreceptor to be highly sensitive to dopamine agonists (this has been well demonstrated; see Carlsson, 1977; Skirboll et al., 1979) but not very sensitive to the action of neuroleptics (this has been observed by some workers (see Iversen et al., 1976) but not by others (see Stromborn, 1981) ).
The present results support the observations of others that ["HIADTN and [3H] apomorphine label multiple binding sites. Our results indicate that, under our assay conditions, ["HIADTN and [3H] apomorphine label two sets of dopaminergic binding sites: the D3 site and a site with high affinity for both neuroleptics and dopamine agonists. The selectivity and affinity of [3H]ADTN and ["Hlapomorphine for various binding sites are dependent upon the tissue and the assay conditions. The labeling of different amounts of these various sites in different species and laboratories may account for the variations in the binding characteristics observed for these ligands. Using selective binding techniques, as described in this paper, the DB and the high affinity neuroleptic sites can, using [3H]ADTN or [3H]apomorphine, be labeled and studied individually.
